Pomalidomide

製品コードS1567 別名:CC-4047

Pomalidomide化学構造

分子量(MW):273.24

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

サイズ 価格(税別)  
In DMSO JPY 17100
JPY 13600
JPY 21900
JPY 63400
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.
特性 A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
ターゲット
TNF-α [1]
(PBMCs)
13 nM
体外試験

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 MVLDfZRwfG:6aXPpeJkhSXO|YYm= MUixNEDPxE1? MlX5NlQhcA>? MlrkdI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GU M4\PTVI3OzN6Mkez
J-CD38 MkPjR5l1d3SxeHnjbZR6KEG|c3H5 NIr2b5oyOCEQvF2= M1;zXVI1KGh? Mn7PdI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GU MX:yOlM{QDJ5Mx?=
R-CD38 M1vOSmN6fG:2b4jpZ4l1gSCDc4PhfS=> NHLFNXEyOCEQvF2= M3PDd|I1KGh? M3HYcpBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= M17GdFI3OzN6Mkez
BC-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT6N|kuOTJ3MDDuUS=> MWK1JIQ> NG\4[oVFVVORwrC= M321NWlEPTB;MUC3JI5ONCCrbnjpZol1eyClZXzsJGlEPTB;MUC3JI5ONCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Ml;uNlYyOTl7M{m=
BCBL-1 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvPfnI{QS1zMkWwJI5O MoLJOUBl MlXKSG1UV8Li MmDZTWM2OD15NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M{PjOlI3OTF7OUO5
JSC-1 NX34Z2k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVizPU0yOjVyIH7N NETldVQ2KGR? MYTEUXNQyqB? NEWxbmRKSzVyPUO0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 MlXENlYyOTl7M{m=
VG-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTkVHc{QS1zMkWwJI5O NVXremJkPSCm MmTBSG1UV8Li MVHJR|UxRTFyMTDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4fW[VI3OTF7OUO5
UMPEL-1 M1TwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[zPU0yOjVyIH7N NHK4SXA2KGR? MVHEUXNQyqB? MVTJR|UxRTN{IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NFn5fW8zPjFzOUmzPS=>
UMPEL-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH5[YE{QS1zMkWwJI5O NIrQU|E2KGR? MWXEUXNQyqB? MkW2TWM2OD1zMUGgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= Mn;aNlYyOTl7M{m=
BC-1 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXezPU0yOjVyIH7N NHzITFg2KGR? MXjEUXNQyqB? M4r2XmlEPTB;N{S0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 MVuyOlEyQTl|OR?=
BCP-1 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCzPU0yOjVyIH7N M2fRV|Uh\A>? M{LrWGROW00EoB?= NWS2cIE1UUN3ME2zPVYhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MnW4NlYyOTl7M{m=
APK-1 NF[wb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3UPGtIOzlvMUK1NEBvVQ>? NH7ZW|Q2KGR? Mlz2SG1UV8Li MnzUTWM2OD1{Mk[gcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= NUDqfmgyOjZzMUm5N|k>
RPMI8226  MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrLXpB{OC5yMT21NEDPxE1? NWjOU4Z5PDhiaB?= NXm0R3dCTE2VT9Mg MnrwTWM2OD16IN88US=> NXvqUFk1OjZyOUe4O|I>
OPM2  MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\qeVcxNjBzLUWwJO69VQ>? NWXBRnZjPDhiaB?= M3jpVmROW00EoB?= M3fpSGlEPTB;MUCg{txO MljxNlYxQTd6N{K=
RPMI8226  MXrGeY5kfGmxbjDBd5NigQ>? MlzzNVAh|ryP M4rhW|Q5KGh? NUXqOXdxTE2VT9Mg M3fEfpN1emWwZ4To[Y5{KGO7dH;wcIF{dWmlLX71Z4xm[XJic3j1eJRtcW6pIH;mJI1VV1JiYX7kJJAudVSRUjDwdo91\Wmw MW[yOlA6Pzh5Mh?=
OPM2  M4Hk[GZ2dmO2aX;uJGF{e2G7 MmjVNVAh|ryP NH:3Vm41QCCq M1;WWWROW00EoB?= NGLmfop{fHKnbnf0bIVveyCleYTvdIxie22rYz3ueYNt\WG{IIPoeZR1dGmwZzDv[kBuXE:UIHHu[EBxNW2WT2KgdJJwfGWrbh?= Mnq1NlYxQTd6N{K=
RPMI8226 NYTjZlk5TnWwY4Tpc44hSXO|YYm= MlrVNE4yNTFyIN88US=> NYK1TFRVPCCq NGrjRWRFVVORwrC= MWfpcoNz\WG|ZYOgWmVITiCvUl7BJIV5eHKnc4Ppc44> M4TpWVI2ODV|OUmw
SH-SY5Y  NFPnb3hCeG:ydH;zbZMhSXO|YYm= MmDtNlXDqM7:Zz;tUC=> MlfuNeKhcA>? NIfX[FJk[XW|ZYOgd5RifGm|dHnjZYxtgSC|aXfubYZq[2GwdDDy[YR2[3Srb36gbY4h[m:2aDDDVGYuKGGwZDDDVGYsS01vaX7keYNm\CCjcH;weI9{cXQEoB?= NGn6[JEzPDl5NUK3Oi=>
JJN3 NH;WeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3xbJQxNjFvMUCwJO69VQ>? MXO3NkBp MWrEUXNQ NX7HepV6cW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? M{PweFI{OTd6M{e4
XG-1 NEDG[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWyNE4yNTFyMDFOwG0> NXHrVWFFPzJiaB?= NHvIbnRFVVOR NWHRSYw1cW6qaXLpeJMh[2WubDDndo94fGh? NFLtbWEzOzF5OEO3PC=>
CD138+  NGHuPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGwMlEuOTByIN88US=> NXy0T28xPzJiaB?= MmrQSG1UVw>? MoXMbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NVrs[m1XOjNzN{izO|g>
XG-1 NVvYfXRSTnWwY4Tpc44hSXO|YYm= MmHlNk8yODBizszN MluyNlQhcA>? NXv1W5g{TE2VTx?= MXTpcohq[mm2czDDR2w{N02LUD2x{tEhdVKQQTDlfJBz\XO|aX;u NELpTpozOzF5OEO3PC=>
U266 NGniUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMlAyNTFyIN88US=> M4r0TFQ56oDLaB?= NV7yUZdJTE2VTx?= MUXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NYrzb4g3OjJ3NUKwNFg>
CRBN60 NGnMcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi1NE4xOS1zMDFOwG0> NFXlZ2c1QOLCiXi= M3X3dmROW09? NH7hcIlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NYfLbIZVOjJ3NUKwNFg>
CRNB75 NIe2TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvPRoUxNjBzLUGwJO69VQ>? M3vE[VQ56oDLaB?= NXHF[oVzTE2VTx?= MUnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MYSyNlU2OjByOB?=
MM.1S NHmxT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL0NE4xOS1zMDFOwG0> MX20PQKBkWh? M1TES2ROW09? MU\zbYdvcW[rY3HueIx6KGmwaHnibZR{KHC{b3zp[oVz[XSrb36gZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODIQvF2= NHTNPY4zOTN6OUOyOy=>
OPM2 NY\pZ3p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjSNE4xOS1zMDFOwG0> MXe0PQKBkWh? M3jx[2ROW09? NH;DUoh{cWewaX\pZ4FvfGy7IHnubIljcXS|IIDyc4xq\mW{YYTpc44h[XRiY3;uZ4VvfHKjdHnvcpMh[XNibH;3JIF{KDBwMEJOwG0> MnroNlE{QDl|Mke=
MM.1S M3fD[GZ2dmO2aX;uJGF{e2G7 NHn1WHYyOCEQvF2= MWS3NkBp NXSxR5IyTE2VTx?= NIDuV45{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA> NVLuOmhFOjF|OEmzNlc>
H929 NGjRZXZHfW6ldHnvckBCe3OjeR?= NUDreXBPOTBizszN MVi3NkBp NUjYWJNCTE2VTx?= MoLqd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJJBzd3SnaX6gcIV3\Wxib3[gR{9GSlEQsjDpd49nd3Kvc9Mg NHPsVoozOTN6OUOyOy=>
OPM2 MWHGeY5kfGmxbjDBd5NigQ>? M325ZlExKM7:TR?= MknlO|IhcA>? MXfEUXNQ NFrOc|V{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA> MlqwNlE{QDl|Mke=
CT26 NWXFZ4RqTnWwY4Tpc44hSXO|YYm= MkHLNU8yOCEQvF2= NFT4PGszPCCq MoPndoVlfWOnczD0bIUhdnWvYnXyd{Bw\iCuaY\lJINwdG:waXXzxsA> NX3FTndEOTl4M{i5O|c>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘 

29496670
体内試験 Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Inhibition of TNF-α synthesis:

TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
細胞試験: [4]
+ 展開
  • 細胞株: Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • 濃度: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • 反応時間: 24 or 48 hours
  • 実験の流れ: For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Disseminated lymphoma-bearing SCID mice
  • 製剤: Dissolved in DMSO to make a 10 mg/mL stock solution and diluted to a final concentration of 1 mg/mL in sterile 0.9% normal saline.
  • 投薬量: 0.5 mg/kg
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 273.24
化学式

C13H11N3O4

CAS No. 19171-19-8
保管
in solvent
別名 CC-4047

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03841565 Withdrawn Neoplastic Plasma Cells 30 Percent or More of Bone Marrow Nucleated Cells|Recurrent Plasma Cell Myeloma Academic and Community Cancer Research United|National Cancer Institute (NCI) March 31 2019 Phase 2
NCT03841565 Withdrawn Neoplastic Plasma Cells 30 Percent or More of Bone Marrow Nucleated Cells|Recurrent Plasma Cell Myeloma Academic and Community Cancer Research United|National Cancer Institute (NCI) March 31 2019 Phase 2
NCT03732703 Not yet recruiting Relapsed Refractory Multiple Myeloma Multiple Myeloma Research Consortium|AbbVie|Celgene Corporation|Eli Lilly and Company|Genentech Inc.|Janssen LP|Takeda March 15 2019 Phase 1|Phase 2
NCT03732703 Not yet recruiting Relapsed Refractory Multiple Myeloma Multiple Myeloma Research Consortium|AbbVie|Celgene Corporation|Eli Lilly and Company|Genentech Inc.|Janssen LP|Takeda March 15 2019 Phase 1|Phase 2
NCT03601806 Not yet recruiting Human Immunodeficiency Virus 1 Positive|Skin Kaposi Sarcoma AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles January 31 2019 Phase 2
NCT03756896 Recruiting Plasma Cell Myeloma Emory University|Amgen January 25 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • 回答:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • 質問2:

    I would like to know if the pomalidomide is racemic or optically active?

  • 回答:

    Our S1567 Pomalidomide is racemic.

TNF-alphaシグナル伝達経路

TNF-alpha Inhibitors with Unique Features

相関TNF-alpha製品

Tags: Pomalidomideを買う | Pomalidomide ic50 | Pomalidomide供給者 | Pomalidomideを購入する | Pomalidomide費用 | Pomalidomide生産者 | オーダーPomalidomide | Pomalidomide化学構造 | Pomalidomide分子量 | Pomalidomide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID